Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond

References

• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015 Sep;125(9):3335–3337. Epub 2015 Sep 1. PMID: 26325031; PMCID: PMC4588312.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021 Jun;13(8):637–644. Epub 2021 Apr 6. PMID: 33820447.
   PubMed Web of Science ®Google Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018 Jan 23;6(1):8. PMID: 29357948; PMCID: PMC5778665.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol. 2021 Mar;17(7):755–757. Epub 2021 Jan 29. PMID: 33508960.
   PubMed Web of Science ®Google Scholar
• Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res. 2019 Aug 2;8:1342. F1000Faculty Rev-1342PMID: 31448088; PMCID: PMC6681627.
   Google Scholar
• Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020 Apr;18(4):479–489. PMID: 32259782.
   PubMed Web of Science ®Google Scholar
• Winer EP, Lipatov O, Im SA, et al. KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr 4;22:499–511. Epub 2021 Mar 4. PMID: 33676601.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019 Jan 1;5(1):74–82. PMID: 30242306; PMCID: PMC6439773.
   PubMed Web of Science ®Google Scholar
• Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019 May 9;17(1):90. PMID: 31068190; PMCID: PMC6507064.
   PubMed Web of Science ®Google Scholar
• Jia H, Truica CI, Wang B, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat. 2017 May 32;32:1–15. Epub 2017 Aug 19. PMID: 29145974.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018 Feb 1;24(3):511–520. Epub 2017 Aug 11. PMID: 28801472; PMCID: PMC5796849.
   PubMed Web of Science ®Google Scholar
• Sporikova Z, Koudelakova V, Trojanec R, et al. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018 Oct;18(5):e841–e850. Epub 2018 Aug 4. PMID: 30146351.
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020 Jun 9;22(1):61. PMID: 32517735; PMCID: PMC7285581.
   PubMed Web of Science ®Google Scholar
• Reddy SM, Carroll E, Nanda R. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020 Mar;20(3):151–158. Epub 2020 Feb 27. PMID: 32067545.
   PubMed Web of Science ®Google Scholar
• Huang W, Ran R, Shao B, et al. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019 Nov;178(1):17–33. Epub 2019 Jul 29. PMID: 31359214.
   PubMed Web of Science ®Google Scholar
• Stovgaard ES, Dyhl-Polk A, Roslind A, et al. Nielsen D. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Res Treat. 2019 Apr;174(3):571–584. Epub 2019 Jan 10. PMID: 30627961.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. IMpassion130 investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44–59. Epub 2019 Nov 27. PMID: 31786121.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817–1828. PMID: 33278935.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, et al. International Immuno-Oncology Biomarker Working Group. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020 Apr;250(5):667–684. Epub 2020 Apr 9. PMID: 32129476.
   PubMed Web of Science ®Google Scholar
• Rozenblit M, Huang R, Danziger N, et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. 2020 Nov8;8(2):e001558. PMID: 33239417; PMCID: PMC7689582.
   PubMed Web of Science ®Google Scholar
• Erber R, Hartmann A. Understanding PD-L1 testing in breast cancer: a practical approach. Breast Care (Basel). 2020 Oct;15(5):481–490. Epub 2020 Oct 6. PMID: 33223991; PMCID: PMC7650134.
   PubMed Web of Science ®Google Scholar
• Lee SE, Park HY, Lim SD, et al. Concordance of programmed death-ligand 1 expression between SP142 and 22C3/SP263 assays in triple-negative breast cancer. J Breast Cancer. 2020 Jun 1;23(3):303–313. PMID: 32595992; PMCID: PMC7311361.
   PubMed Web of Science ®Google Scholar
• Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 2021 Jun;40(2):537–547. Epub 2021 Jun 8. PMID: 34101053; PMCID: PMC8184866.
   PubMed Web of Science ®Google Scholar
• Boman C, Zerdes I, Mårtensson K, et al. Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2021 Jul 1;99:102257. Epub ahead of print. PMID: 34237488.
   PubMed Web of Science ®Google Scholar
• Ahn SG, Kim SK, Shepherd JH, et al. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Jul;188(1):165–178. Epub 2021 Mar 26. PMID: 33770313; PMCID: PMC8233296.
   PubMed Web of Science ®Google Scholar
• Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 2019 Nov21;20(11):82. PMID: 31754897.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Loi S, Adams S, et al. Emens LA. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer. J Natl Cancer Inst. 2021 Jun 7. djab108. Epub ahead of print. PMID: 34097070. DOI:https://doi.org/10.1093/jnci/djab108
   Google Scholar
• Rugo HS, Cortes J, Cescon DW, et al. KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Ann Oncol. 2021;32(suppl_5):S1283–S1346.
   Google Scholar
• Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021 Mar;70(3):607–617. Epub 2020 Oct 5. PMID: 33015734.
   PubMed Web of Science ®Google Scholar
• Badve SS, Penault-Llorca F, Reis-Filho JS, et al. Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130. J Natl Cancer Inst. 2021 Jul 20. djab121. Epub ahead of print. PMID: 34286340. DOI:https://doi.org/10.1093/jnci/djab121
   Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016 Nov;13(11):674–690. Epub 2016 May 17. PMID: 27184417; PMCID: PMC5461122.
   PubMed Web of Science ®Google Scholar
• Da Silva JL, Cardoso Nunes NC, Izetti P, et al. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. 2020 Jan;145:102855. Epub 2019 Dec 20. PMID: 31927455.
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis. Ann Oncol. 2021 Aug;32(8):983–993. Epub 2021 Jul 1. PMID: 34272041.
   PubMed Web of Science ®Google Scholar
• Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019 May 23;17:661–674. PMID: 31205619; PMCID: PMC6558092.
   PubMed Web of Science ®Google Scholar
• Paijens ST, Vledder A, de Bruyn M, et al. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021 Apr;18(4):842–859. Epub 2020 Nov 2. PMID: 33139907; PMCID: PMC8115290.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel). 2021 Feb 1;13(3):558. PMID: 33535621; PMCID: PMC7867133.
   PubMed Web of Science ®Google Scholar
• Lee N, Zakka LR, Mihm MC Jr, et al. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016 Feb;48(2):177–187. Epub 2016 Jan 16. PMID: 27020390.
   PubMed Web of Science ®Google Scholar
• Zou Y, Zou X, Zheng S, et al. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020 Aug 17;12:1758835920940928. PMID: 32874208; PMCID: PMC7436841.
   Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, et al. International TILs working group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international tils working group 2014. Ann Oncol. 2015 Feb;26(2):259–271. Epub2014 Sep 11. PMID: 25214542; PMCID: PMC6267863.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Radosevic-Robin N, Fineberg S, et al. International immuno-oncology biomarker working group on breast cancer. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the international immuno-oncology biomarker working group on breast cancer. Semin Cancer Biol. 2018 Oct;52(Pt 2):16–25. Epub 2017 Oct 9. PMID: 29024776.
   PubMed Web of Science ®Google Scholar
• Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges. Cancers (Basel). 2020 May 29;12(6):1404. PMID: 32486021; PMCID: PMC7352772.
   PubMed Web of Science ®Google Scholar
• Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020 May;31(5):569–581. Epub 2020 Feb 14. PMID: 32278621.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019 Mar 1;30(3):405–411. PMID: 30475947.
   PubMed Web of Science ®Google Scholar
• Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021 Feb 1;113:1005–1016. djab004. Epub ahead of print. PMID: 33523233.
   PubMedGoogle Scholar
• Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 Jan;577(7791):549–555. Epub 2020 Jan 15. PMID: 31942075.
   PubMed Web of Science ®Google Scholar
• Mills CD, Lenz LL, Harris RA, et al. Macrophage-Directed cancer immunotherapy. Cancer Res. 2016 Feb 1;76(3):513–586. Epub 2016 Jan 15. PMID: 26772756; PMCID: PMC4738030.
   PubMed Web of Science ®Google Scholar
• Ahmed FS, Gaule P, McGuire J, et al. PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2020 Oct 15;26(20):5456–5461. Epub 2020 Jul 24. PMID: 32709714; PMCID: PMC7572612.
   PubMed Web of Science ®Google Scholar
• Sugie T. Immunotherapy for metastatic breast cancer. Chin Clin Oncol. 2018 Jun 7;28(3). PMID: 30056730. DOI:https://doi.org/10.21037/cco.2018.05.05
   Google Scholar
• Al-Mahmood S, Sapiezynski J, Garbuzenko OB, et al. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018 Oct;8(5):1483–1507. PMID: 29978332; PMCID: PMC6133085.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019Feb;51(2):202–206. Epub 2019 Jan 14. PMID: 30643254; PMCID: PMC6365097.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264. PMID: 22437870; PMCID: PMC4856023.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019 Jan 1;30(1):44–56. PMID: 30395155; PMCID: PMC6336005.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun. 2021;27:100328. Epub 2021 Feb 2. PMID: 33549983.
   PubMedGoogle Scholar
• Vikas P, Borcherding N, Zhang W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res. 2018 Dec 10;10:6823–6833. PMID: 30573992; PMCID: PMC6292225.
   PubMed Web of Science ®Google Scholar
• Basu A, Ramamoorthi G, Jia Y, et al. Immunotherapy in breast cancer: current status and future directions. Adv Cancer Res. 2019;143:295–349. Epub 2019 May 2. PMID: 31202361.
   PubMed Web of Science ®Google Scholar
• de Melo Gagliato D, Buzaid AC, Perez-Garcia J, et al. Immunotherapy in breast cancer: current practice and clinical challenges. BioDrugs. 2020 Oct;34(5):611–623. PMID: 32870473.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019 Mar;20(3):e175–e186. PMID: 30842061.
   PubMed Web of Science ®Google Scholar
• Fancello L, Gandini S, Pelicci PG, et al. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges8. J Immunother Cancer. 2019 Jul 15;7(1):183. PMID: 31307554; PMCID: PMC6631597.
   PubMed Web of Science ®Google Scholar
• Merino DM, McShane LM, Fabrizio D, et al. TMB harmonization consortium. establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the friends of cancer research tmb harmonization project. J Immunother Cancer. 2020 Mar;8(1):e000147. PMID: 32217756; PMCID: PMC7174078.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527–536. Epub 2021 Jan 8. PMID: 33215952.
   PubMed Web of Science ®Google Scholar
• Chang L, Chang M, Chang HM, et al. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e15–e21. PMID: 28877075.
   PubMedGoogle Scholar
• Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016 Nov;22(11):1342–1350. Epub2016 Oct 3. Erratum in: Nat Med. 2017 Oct 6;23 (10):1241. Erratum in: Nat Med. 2018 Apr 10;24(4):525PMID: 27694933.
   PubMed Web of Science ®Google Scholar
• Svrcek M, Lascols O, Cohen R, et al. MSI/MMR-deficient tumor diagnosis: which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: differences between tumors. Bull Cancer. 2019Feb;106(2):119–128. Epub 2019 Feb 1. PMID: 30713006.
   PubMed Web of Science ®Google Scholar
• Bayraktar S, Batoo S, Okuno S, et al. Immunotherapy in breast cancer. J Carcinog. 2019 May 23;18:2. PMID: 31160888; PMCID: PMC6540776.
   PubMedGoogle Scholar
• Sukumar J, Gast K, Quiroga D, et al. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021 Feb;21(2):135–148. PMID: 33198517; PMCID: PMC8174647.
   PubMed Web of Science ®Google Scholar
• Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016 Feb 15;22(4):813–820. PMID: 26880610.
   PubMed Web of Science ®Google Scholar
• Sivapiragasam A, Ashok Kumar P, Sokol ES, et al. Predictive biomarkers for immune checkpoint inhibitors in metastatic breast cancer. Cancer Med. 2021 Jan;10(1):53–61. Epub 2020 Dec 12. PMID: 33314633; PMCID: PMC7826457.
   PubMed Web of Science ®Google Scholar
• O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015 Nov 19;60(4):547–560. PMID: 26590714.
   PubMed Web of Science ®Google Scholar
• Brandsma I, Fleuren EDG, Williamson CT, et al. Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017 Dec;26(12):1341–1355. Epub 2017 Oct 14. PMID: 28984489; PMCID: PMC6157710.
   PubMed Web of Science ®Google Scholar
• Huang RSP, Li X, Haberberger J, et al. Biomarkers in breast cancer: an integrated analysis of comprehensive genomic profiling and PD-L1 immunohistochemistry biomarkers in 312 patients with breast cancer. Oncologist. 2020 Nov;25(11):943–953. Epub 2020 Sep 14. PMID: 32869930; PMCID: PMC7648336.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021 Apr;30(4):343–350. Epub 2021 Mar 9. PMID: 33645367.
   PubMed Web of Science ®Google Scholar
• Heimes AS, Schmidt M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs. 2019 Jan 1;28:1–5. Epub 2018 Dec 1. PMID: 30474425.
   PubMed Web of Science ®Google Scholar
• McMahon JT, Faraj RR, Adamson DC. Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. Expert Opin Investig Drugs. 2020 Dec;29(12):1389–1406. Epub 2020 Oct 26. PMID: 33040640.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. High tumor mutation burden and other immunotherapy response predictors in breast cancers: associations and therapeutic opportunities. Target Oncol. 2020 Feb;15(1):127–138. PMID: 31741177.
   PubMed Web of Science ®Google Scholar
• Peg V, López-García MÁ, Comerma L, et al. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion. Future Oncol. 2021 Apr;17(10):1209–1218. Epub 2020 Dec 8. PMID: 33289433.
   PubMed Web of Science ®Google Scholar
• Katsuta E, Yan L, Opyrchal M, et al. Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer. Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006680. PMID: 33868461; PMCID: PMC8024454.
   Web of Science ®Google Scholar
• Mahtani R, Kittaneh M, Kalinsky K, et al. Breast cancer therapy expert group (BCTEG). Advances in therapeutic approaches for triple-negative breast cancer. Clin Breast Cancer. 2020 Dec 29. S1526-8209(20)30339-6. Epub ahead of print. PMID: 33781662. DOI:https://doi.org/10.1016/j.clbc.2020.12.011
   Google Scholar
• Bartsch R; ESMO 2020. highlights in breast cancer. Memo. 2021 Apr 30;1–4. Epub ahead of print. PMID: 33968263; PMCID: PMC8090520. DOI:https://doi.org/10.1007/s12254-021-00713-5
   Google Scholar
• Cipriano É, Mesquita A. Emerging therapeutic drugs in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2021 Mar 22;15:11782234211002491. PMID: 33814914; PMCID: PMC7989121.
   Web of Science ®Google Scholar
• Nagayama A, Vidula N, Bardia A. Novel therapies for metastatic triple-negative breast cancer: spotlight on immunotherapy and Antibody-Drug conjugates. Oncology (Williston Park). 2021 May 13;35(5):249–254. PMID: 33983696.
   PubMedGoogle Scholar
• Young JA, Tan AR. Targeted treatment of triple-negative breast cancer. Cancer J. 2021 Jan-Feb 1;27(1):50–58. PMID: 33475293.
   PubMed Web of Science ®Google Scholar
• Frankel T, Lanfranca MP, Zou W. The role of tumor microenvironment in cancer immunotherapy. Adv Exp Med Biol. 2017;1036:51–64. PMID: 29275464.
   PubMed Web of Science ®Google Scholar
• Quagliariello V, De Laurentiis M, Cocco S, et al. NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. Int J Mol Sci. 2020 Oct 21;21(20):7802. PMID: 33096896; PMCID: PMC7589802.
   Web of Science ®Google Scholar
• Rizzo A, Dadduzio V, Ricci AD, et al., Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs. 2021 Jun 30. 1–8. Epub ahead of print. PMID: 34167433. DOI:https://doi.org/10.1080/13543784.2021.1948532.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opin Investig Drugs. 2021 Aug 30. 1–9. Epub ahead of print. PMID: 34429006. DOI:https://doi.org/10.1080/13543784.2021.1972969.
   Google Scholar
• Quagliariello V, Passariello M, Rea D, et al. Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models. J Pers Med. 2020 Oct 19;10(4):179. PMID: 33086484; PMCID: PMC7711520.
   Web of Science ®Google Scholar
• Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021 Jul 23;20(1):150. PMID: 34301253; PMCID: PMC8305868.
   PubMed Web of Science ®Google Scholar